Skip to content

Relationship of Periostin and ODI, EQ-5D

Study of Correlation Between Serum Periostin Levels and Oswestry Disability Index and EQ-5D

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07664904
Enrollment
53
Registered
2026-06-24
Start date
2026-06-22
Completion date
2027-02-27
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intervertebral Disc Disease

Brief summary

The intervertebral disc degeneration (IVDD) is a widely recognized musculoskeletal disorder that impose a substantial socioeconomic burden and respresents one of the most important causes of low back pain. IVDD can result from a variety of factors, including aging, obesity, genetic predispositioin, degeneration of of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress. The IVD consists of a central gelatinous nucleus pulposus (NP), an outer annulus fibrosus (AF), and superior and inferior cartilaginous endplates. The NP and AF produce a water-rich extracellular matrix (ECM), which is essential for normal trunk function. Dysfunction of the NP and AF, together with excessive metabolic activity of the enplates triggered by various intrinsic and extrinsic stimuli, leads to endplate degeneration and calcification, and ultimately to IVDD. In addition to aging and mechanical overload, increased oxidative stress and pro-inflammatrory cytokine secretion further accelerate the progression of IVDD. Periostin is an ECM protein which is associated with mechanical stress, inflammation, and aging, and is known to be closely involved in the development and progression of IVDD. Periostin binds to ECM molecule within the IVD and participates in its maintenance and repair; however, excessive ECM turn over drives IVD degeneration and its progression. Periostin influences IVD degeneration through mechanical stress and inflammatory pathways, and serum periostin levels are elevated in patients with severe IVD degeneration. A recent study demonstrated strong corrrelation between serum periostin concentration and the Pfirmann grading system. The Oswestry disability index is a validated scale that measures functional disability in patients with spinal pain, and the EQ-5D is a breif questionnaire used to assess health related quality of life. Because serum periostin levels reflect the severity of IVDD, periostin may also influence patient's functional disability and quality of life. However, whether serum periostin concentration correlates with functional disability and quality of life has not yet been studied.

Interventions

blood sampling to detect the level of periostin and cytokine

Sponsors

Keimyung University Dongsan Medical Center
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* lumbar disc herniation * lumbar spinal canal stenosis * patients who have MRI * patients who can fill in the ODI and EQ5D without other's help

Exclusion criteria

* allergic disease * allergic rhinitis * asthma * atopic dermatitis * chronic sinusitis * history of cancer * fracture within 6 months * severe osteoporosis * knee osteoarthritis * hip osteoarthrtis * spinal surgery within 6 months * myocardiac infarction * heart failure * liver cirrhosis * chronic kidney disease * rhematoid disease * systemic lupus erythematosus * ankylosing spondylitis * Crohn's disease * Ulcerative colitis * systemic steroid user * acute or chronic infection * BMI \> 30 * uncontrolled hypertension * uncontrolled diabetes * recent history of vaccination

Design outcomes

Primary

MeasureTime frame
Identifying the correlation of periostin level and ODI and EQ5DDay1

Secondary

MeasureTime frame
Identifying the correlation of the periostin level and Cytokine level and Pfirmann gradingDay1

Countries

South Korea

Contacts

CONTACTJIHEE Hong
swon13@daum.net01046794343

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026